Literature DB >> 26674711

Prevalence of Multidrug Resistant Pulmonary Tuberculosis in North Bihar.

Sunita Tripathy1, Rajesh Kumar2, Surya Deo Singh3.   

Abstract

INTRODUCTION: Multidrug resistant tuberculosis (MDR-TB) is caused by Infection with Mycobacterium tuberculosis which is resistant to both isoniazid (INH) and rifampicin (RIF), with or without any other anti tubercular drug. It is caused by resistant mutant strains due to inadequate treatment and poor compliance. Due to time taking conventional diagnostic methods, drug resistant strains continue to spread. Therefore rapid diagnosis and treatment of MDR-TB strains are prerequisites for the worldwide fight against TB.
OBJECTIVE: To determine the prevalence of MDR TB in North Bihar by molecular diagnostic method and to facilitate early diagnosis and treatment. Also, to find out the number of those diagnosed cases who were successfully initiated the treatment in MDR TB Centre of DMCH.
MATERIALS AND METHODS: This six month observational study was carried out in IRL Darbhanga, Damien TB research Centre of the Darbhanga Medical College and Hospital, Bihar, India. During the period of February-July 2014, 256 sputum samples were collected from suspected cases of multidrug resistant tuberculosis, from 6 districts of North Bihar around Darbhanga. These samples were subjected to routine microscopy and culture to detect Mycobacterium tuberculosis. Positive cases were subjected to drug sensitivity test by a molecular diagnostic method, Using Genotype MTBDR plus kit. RESULT: Out of 256 sputum samples from suspected cases of MDR TB, 122 cases were microscopy positive for tuberculosis. Among these 122 cases, tuberculosis was confirmed by PCR in 114 cases. Finally with the help of Line Probe Assay (LPA), 39(15%) samples were found to have resistance to both INH and Rifampicin. Male female ratio was 4:1.
CONCLUSION: The Prevalence of Multi drug resistant pulmonary tuberculosis in North Bihar is 15%. It needs early diagnosis by molecular diagnostic method and prompt treatment to reduce the spread of MDR TB cases.

Entities:  

Keywords:  DR TB (Drug Resistant Tuberculosis); INH (Isoniazide); IRL (Intermediate referral laboratory); LPA (Line Probe Assay); Programmatic management of Drug Resistant TB (PMDT)

Year:  2015        PMID: 26674711      PMCID: PMC4668440          DOI: 10.7860/JCDR/2015/14024.6793

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

Review 1.  Drug-resistant and multidrug-resistant tubercle bacilli.

Authors:  B Petrini; S Hoffner
Journal:  Int J Antimicrob Agents       Date:  1999-10       Impact factor: 5.283

2.  Primary and acquired drug resistance patterns of Mycobacterium tuberculosis isolates in India: a multicenter study.

Authors:  Jitendra Prasad Mathuria; Jai Kumar Samaria; Govind Narayan Srivastava; Bharat Lal Mathuria; Sanjay Kumar Ojha; Shampa Anupurba
Journal:  J Infect Public Health       Date:  2013-07-02       Impact factor: 3.718

Review 3.  Multidrug-resistant tuberculosis.

Authors:  S K Sharma; A Mohan
Journal:  Indian J Med Res       Date:  2004-10       Impact factor: 2.375

4.  The global burden of tuberculosis--combating drug resistance in difficult times.

Authors:  Peter R Donald; Paul D van Helden
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

5.  Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran.

Authors:  M Metanat; B Sharifi-Mood; Sh Shahreki; S H Dawoudi
Journal:  Iran Red Crescent Med J       Date:  2012-01-01       Impact factor: 0.611

6.  Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.

Authors:  H L David
Journal:  Appl Microbiol       Date:  1970-11

7.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  A Pablos-Méndez; M C Raviglione; A Laszlo; N Binkin; H L Rieder; F Bustreo; D L Cohn; C S Lambregts-van Weezenbeek; S J Kim; P Chaulet; P Nunn
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

8.  Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa.

Authors:  Jason R Andrews; Neel R Gandhi; Prashini Moodley; N Sarita Shah; Louise Bohlken; Anthony P Moll; Manormoney Pillay; Gerald Friedland; A Willem Sturm
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

9.  Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients.

Authors:  Surendra K Sharma; Sanjeev Kumar; P K Saha; Ninoo George; S K Arora; Deepak Gupta; Urvashi Singh; M Hanif; R P Vashisht
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

10.  Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program.

Authors:  Yatin N Dholakia; Divya P Shah
Journal:  Lung India       Date:  2013-10
View more
  1 in total

1.  Performance of revised national tuberculosis control program in Bihar: A situational analysis.

Authors:  Bijit Biswas; Abhishek Kumar; Neeraj Agarwal
Journal:  J Family Med Prim Care       Date:  2020-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.